Fig. 3From: Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infectionKaplan–Meier analysis of the overall survival (OS) of 43 patients with HCC. Forty-three patients with HCC were followed-up for 25 months. A Kaplan–Meier analysis showed that patients with HCC with serum RASSF1A positivity (n = 24) were more likely to experience a worse OS (P = 0.017)Back to article page